PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
42.50%
Net income growth above 1.5x AVXL's 4.86%. David Dodd would see a clear bottom-line advantage if it is backed by stable operations.
0.99%
D&A growth of 0.99% while AVXL is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.02%
Both cut yoy SBC, with AVXL at -19.06%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
66.71%
Slight usage while AVXL is negative at -37.26%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Lower AP growth vs. AVXL's 3798.17%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
-209.52%
Both reduce yoy usage, with AVXL at -190.43%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
100.00%
Lower 'other non-cash' growth vs. AVXL's 200.00%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
51.97%
Some CFO growth while AVXL is negative at -28.53%. John Neff would note a short-term liquidity lead over the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.02%
Both yoy lines negative, with AVXL at -100.00%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.